Premium
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross‐sectional survey on the prevalence of fake antimalarials
Author(s) -
Dondorp A. M.,
Newton P. N.,
Mayxay M.,
Van Damme W.,
Smithuis F. M.,
Yeung S.,
Petit A.,
Lynam A. J.,
Johnson A.,
Hien T. T.,
McGready R.,
Farrar J. J.,
Looareesuwan S.,
Day N. P. J.,
Green M. D.,
White N. J.
Publication year - 2004
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2004.01342.x
Subject(s) - artesunate , counterfeit , mefloquine , malaria , artemisinin , counterfeit drugs , southeast asia , traditional medicine , environmental health , medicine , plasmodium falciparum , geography , ancient history , archaeology , immunology , history
Summary Objective To assess the prevalence of counterfeit antimalarial drugs in Southeast (SE) Asia. Design Cross‐sectional survey. Setting Pharmacies and shops selling antimalarial drugs in Myanmar (Burma), Lao PDR, Vietnam, Cambodia and Thailand. Main outcome measures Proportion of artemisinin derivatives or mefloquine containing drugs of substandard quality. Results Of the 188 tablet packs purchased which were labelled as ‘artesunate’ 53% did not contain any artesunate. All counterfeit artesunate tablets were labelled as manufactured by ‘Guilin Pharma’, and refinements of the fake blisterpacks made them often hard to distinguish from their genuine counterparts. No other artemisinin derivatives were found to be counterfeited. Of the 44 mefloquine samples, 9% contained <10% of the expected amount of active ingredient. Conclusions An alarmingly high proportion of antimalarial drugs bought in pharmacies and shops in mainland SE Asia are counterfeit, and the problem has increased significantly compared with our previous survey in 1999–2000. This is a serious threat to public health in the region.